WuXi AppTec Co Ltd (603259) - Total Liabilities
Based on the latest financial reports, WuXi AppTec Co Ltd (603259) has total liabilities worth CN¥23.41 Billion CNY (≈ $3.43 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore WuXi AppTec Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
WuXi AppTec Co Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how WuXi AppTec Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See WuXi AppTec Co Ltd (603259) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
WuXi AppTec Co Ltd Competitors by Total Liabilities
The table below lists competitors of WuXi AppTec Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank Central Asia Tbk
JK:BBCA
|
Indonesia | Rp1242.32 Trillion |
|
ArcelorMittal SA ADR
NYSE:MT
|
USA | $41.06 Billion |
|
DnB ASA
OL:DNB
|
Norway | Nkr3.54 Trillion |
|
Ferrovial SE
NASDAQ:FER
|
USA | $19.75 Billion |
|
Danske Bank A/S
CO:DANSKE
|
Denmark | Dkr3.62 Trillion |
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
USA | $12.04 Billion |
|
Cheniere Energy Inc
NYSE MKT:LNG
|
USA | $33.64 Billion |
|
Flex Ltd
F:FXI
|
Germany | €15.70 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down WuXi AppTec Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see WuXi AppTec Co Ltd (603259) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how WuXi AppTec Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for WuXi AppTec Co Ltd (2014–2024)
The table below shows the annual total liabilities of WuXi AppTec Co Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥21.24 Billion ≈ $3.11 Billion |
+17.01% |
| 2023-12-31 | CN¥18.15 Billion ≈ $2.66 Billion |
+2.19% |
| 2022-12-31 | CN¥17.76 Billion ≈ $2.60 Billion |
+8.51% |
| 2021-12-31 | CN¥16.37 Billion ≈ $2.40 Billion |
+20.61% |
| 2020-12-31 | CN¥13.57 Billion ≈ $1.99 Billion |
+14.74% |
| 2019-12-31 | CN¥11.83 Billion ≈ $1.73 Billion |
+162.76% |
| 2018-12-31 | CN¥4.50 Billion ≈ $658.78 Million |
-22.94% |
| 2017-12-31 | CN¥5.84 Billion ≈ $854.93 Million |
+29.02% |
| 2016-12-31 | CN¥4.53 Billion ≈ $662.63 Million |
+39.06% |
| 2015-12-31 | CN¥3.26 Billion ≈ $476.50 Million |
+22.44% |
| 2014-12-31 | CN¥2.66 Billion ≈ $389.18 Million |
-- |
About WuXi AppTec Co Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more